REGN 8-K Current Reports
REGENERON PHARMACEUTICALS, INC. - 302 current reports
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 6, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 million. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter. Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 17, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 17, 2026, detailing the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. The report confirms the election of Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, shareholders provided advisory approval for executive compensation. Key outcomes include the successful election of all nominated directors, indicating strong shareholder confidence in the current board's leadership. The ratification of the auditor received substantial support, reinforcing the company's commitment to financial transparency and robust auditing practices. The advisory vote on executive compensation also passed with a significant majority, suggesting shareholder alignment with the company's compensation philosophy for its named executive officers.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 29, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 29, 2026, to report its financial and operating results for the first quarter ended March 31, 2026. The key details of these results are provided in a press release, which is incorporated by reference as Exhibit 99.1 to this filing. Investors should note that the information furnished under Item 2.02, including the press release, is not considered "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 unless expressly incorporated into a future SEC filing. Investors seeking specific financial performance metrics, revenue figures, pipeline updates, or forward-looking guidance for the first quarter of 2026 should refer directly to the press release filed as Exhibit 99.1.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 8, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose anticipated financial results for the first quarter of 2026. The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis. This charge is primarily associated with equity securities purchased and payments made under collaboration and licensing agreements. The most significant impact for investors is the expected negative effect of this IPR&D charge on both GAAP and non-GAAP net income per diluted share, estimated at $0.81 for the first quarter of 2026. It's important to note that these are preliminary estimates, subject to finalization of financial closing procedures, and actual results could differ. The company also highlighted that acquired IPR&D charges are inherently unpredictable and not typically forecasted.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 30, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on January 29, 2026, to announce its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release detailing these results is attached as Exhibit 99.1 and is incorporated by reference. Investors should refer to this press release for specific figures related to revenue, profitability, and operational performance. This filing is crucial for understanding the company's recent financial health and its trajectory heading into the new fiscal year. The information is being furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, meaning it does not automatically update previous SEC filings. Investors should consult the press release directly for comprehensive details.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 12, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 12, 2026, providing a corporate update and preliminary unaudited financial information for the fourth quarter and full year 2025. The update, delivered at the J.P. Morgan Healthcare Conference, highlighted two key financial items: an anticipated acquired in-process research and development (IPR&D) charge of approximately $19 million, expected to reduce Q4 2025 diluted earnings per share by roughly $0.14 on both a GAAP and non-GAAP basis. This charge reflects investments in early-stage development projects. Additionally, the company reported a $60 million charge to selling, general, and administrative expenses in Q4 2025 related to its matching program for donations to Good Days, a non-profit supporting retinal disease research. Regeneron matched the $60 million in donations received by the Fund for this initiative.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 28, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2025. The company issued a press release on October 28, 2025, detailing these results, which is being furnished as an exhibit to this filing. Investors should refer to the press release (Exhibit 99.1) for specific financial figures and operational updates, as it contains the core information regarding the company's performance during the period. The filing itself primarily serves as a notification and mechanism to incorporate the press release into the SEC's public record. While the 8-K does not contain the detailed financial tables or management commentary directly, the attached press release is the key document for understanding Regeneron's recent performance and outlook. Investors are advised to review this press release thoroughly for a comprehensive understanding of the reported results.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 6, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis for the third quarter of 2025. This charge is primarily linked to an $80 million upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 1, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2025, to report its financial and operating results for the second quarter ended June 30, 2025. The primary purpose of this filing is to furnish the accompanying press release (Exhibit 99.1) which contains detailed financial and operational performance metrics for the period. Investors should refer to this press release for specific figures regarding revenue, profitability, and key product performance. This report serves as the official notification of the company's quarterly performance. While the 8-K itself is brief, it directs stakeholders to the press release for the substantive financial disclosures. Investors are advised to review the press release for insights into Regeneron's strategic progress, any notable product updates, and forward-looking guidance, which will be crucial for assessing the company's current valuation and future prospects.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 18, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing the outcomes of its 2025 Annual Meeting of Shareholders held on June 13, 2025. The key takeaways for investors revolve around significant governance changes and shareholder confidence in the company's direction and leadership. Shareholders overwhelmingly re-elected all Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025, indicating strong support for the current board and financial oversight. Furthermore, investors approved an advisory vote on executive compensation, demonstrating confidence in the company's compensation practices. A notable governance shift occurred with the approval to declassify the board of directors, moving towards a more standard annual election of all board members. However, proposals to eliminate certain supermajority vote requirements for specific charter amendments did not pass, suggesting a desire among some shareholders for existing protections or a cautious approach to altering these provisions.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 29, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on April 28, 2025, to report its first quarter 2025 financial and operating results. The key details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for the specific financial performance and operational achievements during the quarter ended March 31, 2025. The filing itself primarily serves as a notification of the release of this information, rather than containing extensive new disclosures within the 8-K document itself.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 4, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing its financial and operating results for the fourth quarter and full year ended December 31, 2024. The report also announces significant capital allocation decisions by the company's board of directors, marking a new phase in returning value to shareholders. Investors should note the initiation of a quarterly cash dividend program and a substantial share repurchase authorization alongside the earnings release. The company declared its inaugural quarterly cash dividend of $0.88 per share, payable on March 20, 2025, to shareholders of record on February 20, 2025. This signifies a commitment to consistent shareholder returns. Furthermore, Regeneron has authorized an additional $3.0 billion for share repurchases, underscoring confidence in its financial position and the company's valuation. The full details of the financial and operating results are available in the accompanying press release (Exhibit 99.1).
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 13, 2025)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2025, to provide business updates and highlights from its clinical pipeline presented at the 43rd Annual J.P. Morgan Healthcare Conference. The filing includes preliminary, unaudited financial information for the fourth quarter and full year 2024, which is subject to finalization. Investors should note that the company anticipates an acquired in-process research and development (IPR&D) charge of approximately $14 million on a pre-tax basis for Q4 2024, primarily related to asset acquisitions. This charge is expected to reduce GAAP and non-GAAP net income per diluted share by approximately $0.11 for the quarter. The company has also incorporated by reference a press release and conference presentation, which are expected to contain further details on its pipeline and strategic updates. While this information is furnished to the SEC, it is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act unless expressly incorporated into a filing. Investors are advised to review the full details within the referenced exhibits for a comprehensive understanding of Regeneron's recent performance and future outlook.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 31, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 31, 2024, to report its financial and operating results for the third quarter ended September 30, 2024. The key information is contained within the press release, furnished as Exhibit 99.1, which details the company's performance during the period. Investors should refer to this press release for specific financial metrics, revenue figures, and operational updates. While the 8-K itself is a procedural filing, the attached press release is the substantive document for understanding Regeneron's third-quarter performance. This filing serves as the official notification of these results to the market, and the press release provides the necessary details to assess the company's progress and financial health as of the end of September 2024.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 7, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on October 7, 2024, providing a preliminary update on its expected financial results for the third quarter of 2024. The company anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $56 million on a pre-tax basis. This charge is a result of development milestone and up-front payments tied to collaboration and licensing agreements. This IPR&D charge is projected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43 for the third quarter. Investors should note that these are preliminary estimates, and the actual results are subject to the company's financial statement closing procedures and could differ. Regeneron emphasizes that acquired IPR&D charges are inherently unpredictable due to the uncertainty in timing and magnitude of such transactions, and therefore are not typically forecasted.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 1, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2024, to report its financial and operating results for the second quarter ended June 30, 2024. The key information is contained within the press release furnished as Exhibit 99.1 to the filing. Investors should review this press release for detailed insights into the company's performance during the quarter, including revenue generation, profit margins, and strategic updates. This filing serves as the official notification of REGN's Q2 2024 performance. While the 8-K itself is brief, the attached press release is the primary source of information for understanding the company's financial health, operational achievements, and outlook. Investors are encouraged to access and analyze Exhibit 99.1 for a comprehensive understanding of the company's recent results and any forward-looking statements.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 8, 2024)
Regeneron Pharmaceuticals, Inc. has filed a Current Report on Form 8-K to provide preliminary insights into its second quarter 2024 financial results. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $24 million. This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter. While these figures are preliminary and subject to closing procedures, they offer investors an early look at a specific cost impacting the quarter's profitability.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 20, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report detailing the outcomes of its 2024 Annual Meeting of Shareholders held on June 14, 2024. The primary focus of this filing is the voting results on several key proposals, including the election of directors, ratification of its independent auditor, advisory vote on executive compensation, and a shareholder proposal regarding simple majority voting. All proposals presented to shareholders, with the exception of one, received strong support, indicating continued confidence from the company's investors in its governance and operational direction. Of particular note, all nominated directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was overwhelmingly ratified. The advisory vote on executive compensation also passed. However, a shareholder proposal advocating for simple majority voting requirements also received a majority of the votes cast, suggesting a desire among some shareholders for changes in the company's voting structure. Investors should monitor any subsequent actions or responses from the company regarding this approved shareholder proposal.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 2, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 2, 2024, to report its financial and operating results for the first quarter ended March 31, 2024. The press release, filed as Exhibit 99.1, contains the detailed financial data and operational performance for the period. Investors should refer to this press release for comprehensive insights into the company's recent performance. While the 8-K itself is a brief filing, its primary purpose is to officially submit the Q1 2024 earnings press release for public record. This press release will contain key financial metrics such as revenue, earnings per share (EPS), and potentially updates on product sales, pipeline advancements, and strategic outlook. Investors are encouraged to review Exhibit 99.1 for a full understanding of Regeneron's Q1 performance and forward-looking statements.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 2, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on February 2, 2024, announcing its financial and operating results for the fourth quarter and full year ended December 31, 2023. The report primarily consists of a press release that details these results, which is furnished as an exhibit. Investors should refer to this press release for a comprehensive overview of the company's performance during the period. While the 8-K itself is brief, the accompanying press release (Exhibit 99.1) contains the critical financial metrics and operational updates that will be of most interest to shareholders. This includes details on revenue, earnings per share, and potentially insights into key drug performance and pipeline developments. Investors are advised to carefully review the furnished press release for specific figures and forward-looking statements.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 31, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) has announced a planned succession in its finance leadership team. Effective February 5, 2024, following the filing of their 2023 Form 10-K, Christopher Fenimore will be appointed as Senior Vice President, Finance and Chief Financial Officer, succeeding the retiring Robert E. Landry. Concurrently, Jason Pitofsky will be promoted to Vice President, Controller. This transition is part of a previously disclosed CFO succession plan. Mr. Fenimore, with extensive experience within Regeneron and prior roles in the biotech and finance sectors, will see his 2024 base salary adjusted to $660,000 and received a significant equity award in December 2023 valued at $5 million. Mr. Pitofsky's appointment to Controller is a promotion from his previous role as VP, Accounting and Financial Reporting, with no immediate changes to his compensation. Investors can view this as a continuation of internal talent development and a structured handover of critical financial oversight.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 8, 2024)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on January 8, 2024, providing a corporate update that includes preliminary fourth quarter 2023 financial insights and details on an acquired in-process research and development (IPR&D) charge. The company shared preliminary U.S. net product sales for EYLEA® HD (aflibercept) Injection 8 mg at approximately $123 million and for EYLEA® (aflibercept) Injection at approximately $1.34 billion for the fourth quarter of 2023. These figures indicate continued strong performance from the EYLEA franchise, with EYLEA HD contributing a significant initial amount. Additionally, Regeneron anticipates a $30 million pre-tax acquired IPR&D charge related to an extension of its collaboration with Intellia Therapeutics, Inc. This charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.21 for the fourth quarter. While these are preliminary, unaudited figures, the update provides investors with an early look at key revenue drivers and R&D investment impacting the company's financial performance.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 2, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 2, 2023, to furnish a press release detailing its financial and operating results for the third quarter ended September 30, 2023. The core of this filing is the announcement of these results, which are crucial for investors to assess the company's performance and future outlook. While the 8-K itself is a brief report, it directs investors to the accompanying press release (Exhibit 99.1) for the detailed financial figures and operational updates. Investors should focus on the data presented in the press release, which typically includes revenue figures, earnings per share, key product sales, and updates on the company's pipeline and strategic initiatives. This information will be vital for understanding the trajectory of Regeneron's key growth drivers and the overall health of its business during the reporting period. The filing serves as the official notification of these results, with the press release providing the comprehensive details.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 5, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose an expected $100 million pre-tax acquired in-process research and development (IPR&D) charge for the third quarter of 2023. This charge is primarily related to a development milestone payment for the Phase 1 ALN-APP program in early-onset Alzheimer's disease, stemming from Regeneron's collaboration with Alnylam Pharmaceuticals, Inc. This IPR&D charge is anticipated to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.78 for the quarter. While this charge will impact reported earnings, it represents a milestone achievement in the company's research pipeline. Regeneron notes that these IPR&D charges are inherently unpredictable in timing and magnitude and are therefore not typically forecasted.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Sep 8, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing significant changes within its board of directors and executive leadership. Notably, the company announced the retirement of its Chief Financial Officer, Robert E. Landry, who has served in that capacity since 2013. Mr. Landry plans to retire in February 2024, and the company has appointed Christopher Fenimore, currently Senior Vice President, Controller, as his successor, ensuring a smooth transition in financial leadership. In addition to the CFO transition, Regeneron has elected two new independent directors to its Board: Dr. Kathryn Guarini and Dr. David P. Schenkein. These appointments are intended to fill existing vacancies and strengthen the Board's expertise. The report also discloses the departure of Dr. Marc Tessier-Lavigne as a director due to potential conflicts arising from increased involvement with other companies. These leadership changes, while significant, are presented as strategic moves to ensure continued strong governance and financial oversight at Regeneron.
REGENERON PHARMACEUTICALS, INC. 8-K/A Report, Shareholder Vote Results (Sep 8, 2023)
This filing is an amendment to a previous 8-K report and serves to clarify Regeneron Pharmaceuticals, Inc.'s decision regarding the frequency of shareholder advisory votes on executive compensation. The company's Board of Directors, accepting the recommendation of its Compensation and Corporate Governance committees, has determined that these advisory votes will continue to be held annually. This decision follows a shareholder vote at the 2023 Annual Meeting of Shareholders held on June 9, 2023, where the option for a one-year frequency received a majority of the votes cast. The amendment, filed on September 7, 2023, with an event date of June 8, 2023, is a procedural update to formally disclose this outcome and the Board's subsequent confirmation.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 3, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on August 3, 2023, to announce its financial and operating results for the second quarter ended June 30, 2023. The primary purpose of this filing is to furnish the associated press release, which contains the detailed results and operational updates. Investors should refer to the press release (Exhibit 99.1) for the most comprehensive information regarding REGN's performance during the quarter.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Bylaw Amendment (Jun 14, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 13, 2023, detailing key corporate governance actions and shareholder vote outcomes from its Annual Meeting held on June 9, 2023. The most significant governance change involves an amendment to the company's By-Laws to implement its previously disclosed Board leadership succession plan, allowing for the election of two Co-Chairs of the Board. Shareholders overwhelmingly approved routine matters, including the election of Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023, and the advisory vote on executive compensation. The company will continue with annual advisory votes on executive compensation. A shareholder proposal related to access to medicine in intellectual property protection was not approved.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 4, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 4, 2023, to announce its first-quarter 2023 financial and operating results via a press release. While the 8-K itself is brief and primarily serves to incorporate the press release, the key investor information lies within that furnished document. Investors should review the press release for details on revenue, earnings, product performance, and any forward-looking statements or strategic updates from the company during the first quarter of 2023. This filing indicates that the company met its reporting obligations by providing timely financial updates. The press release, incorporated by reference, will contain the specifics regarding the company's performance, including key metrics for its approved products and pipeline developments. Investors interested in Regeneron's performance should look to the details within the press release for a comprehensive understanding of the quarter's outcomes and management's commentary.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Apr 17, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) announced a significant leadership transition in its upcoming 2023 Annual Meeting of Shareholders. Dr. P. Roy Vagelos, the current Chair of the Board, has decided not to stand for re-election. This marks the end of his tenure, during which he will continue to serve until the conclusion of the meeting on June 9, 2023. The company has stated that Dr. Vagelos's decision was not due to any disagreements regarding the company's operations or policies.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 10, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 10, 2023, to disclose an expected acquired in-process research and development (IPR&D) charge for the first quarter of 2023. This charge is primarily related to an upfront payment for their collaboration and license agreement with Sonoma Biotherapeutics, Inc. The company anticipates a pre-tax IPR&D charge of approximately $56 million, which is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $0.42 for the quarter. While this charge is a notable event impacting short-term profitability per share, investors should note that such IPR&D charges are inherently unpredictable and are not typically forecasted by the company. The disclosed figures are preliminary estimates and are subject to finalization of the company's financial closing procedures. Investors should monitor future filings for finalized financial results and strategic updates regarding the Sonoma Biotherapeutics collaboration.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Mar 29, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing the execution of Third Amended and Restated Agreements related to a participation agreement, lease, and guaranty. These agreements, effective March 27, 2023, involve Old Saw Mill Holdings LLC as lessee and BA Leasing BSC, LLC as lessor, with Bank of America, N.A. serving as administrative agent. Regeneron Pharmaceuticals, Inc. itself, along with Regeneron Healthcare Solutions, Inc. and Regeneron Genetics Center LLC, are acting as guarantors under these new arrangements.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 3, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 3, 2023, to report its financial and operating results for the fourth quarter and full year ended December 31, 2022. The key details of these results are provided in a press release, which is furnished as an exhibit to this filing. Investors should refer to this press release for specific financial metrics, including revenue, earnings, and updates on key product performance and pipeline developments, which are crucial for understanding the company's current financial health and future outlook.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 9, 2023)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on January 9, 2023, providing preliminary unaudited financial updates and corporate developments discussed at the J.P. Morgan Healthcare Conference. The company reported strong preliminary U.S. net product sales for EYLEA® (aflibercept) Injection, reaching approximately $6.26 billion for the full year 2022, with $1.50 billion in the fourth quarter. However, fourth-quarter EYLEA sales were impacted by a temporary shift to off-label use of compounded Avastin® and a temporary closure of a patient co-pay assistance fund. Encouragingly, recent data suggests the shift to off-label Avastin is beginning to reverse. Additionally, Regeneron anticipates a $30 million acquired in-process research and development (IPR&D) charge in Q4 2022 and full-year 2022 results, related to an upfront payment for a collaboration with CytomX Therapeutics, Inc. This charge is expected to reduce GAAP and non-GAAP diluted earnings per share by approximately $0.21 for the fourth quarter. Investors should note that these are preliminary, unaudited figures, subject to change upon finalization of financial statements.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Dec 20, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) has entered into a new $750 million senior unsecured five-year revolving credit facility, replacing its previous facility of the same size. This new credit agreement, effective December 19, 2022, provides Regeneron with financial flexibility for working capital needs and general corporate purposes. The facility features a variable interest rate tied to SOFR or alternate base rate, plus an applicable margin that adjusts based on the company's debt rating and leverage ratio. Notably, the agreement includes an option for Regeneron to incorporate environmental, social, and governance (ESG) targets to potentially adjust pricing, aligning with increasing investor focus on sustainability metrics.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 3, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2022. The key information is detailed in the press release furnished as Exhibit 99.1, which provides the company's performance metrics for the period. Investors should review the press release for specific details on revenue, earnings, and any forward-looking statements or business developments announced. This filing serves as the official notification of the quarterly results and is crucial for understanding the company's recent financial standing and operational achievements.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Oct 3, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) announced an important change to its Board of Directors through an 8-K filing on October 3, 2022. The company has elected Craig B. Thompson, M.D. as a new director, expanding the Board from 12 to 13 members. Dr. Thompson's appointment is effective immediately and he will serve until the 2023 Annual Shareholder Meeting. This addition signifies a potential strengthening of the Board's expertise, particularly in technology, as Dr. Thompson has also been appointed to the Board's Technology Committee. Investors should note that Dr. Thompson's compensation will align with the company's existing non-employee director compensation structure, as previously detailed in their proxy statement. There are no disclosed understandings or arrangements with other parties regarding his selection. This move is a governance update that could impact strategic oversight and technological direction for Regeneron.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 3, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 3, 2022, primarily to report its financial and operating results for the second quarter ended June 30, 2022. The key information is contained within the press release furnished as Exhibit 99.1. Investors should review this press release for details on the company's performance, including revenue, earnings, and any significant operational updates or strategic developments during the quarter. This filing serves as the official channel for disseminating the company's quarterly financial performance. While the 8-K itself is brief, the attached press release contains the critical data points that stakeholders will use to assess Regeneron's current financial health and its trajectory. It's important to note that the information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, but it is the primary source of the disclosed financial results.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 15, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 15, 2022, detailing the outcomes of its 2022 Annual Meeting of Shareholders held on June 10, 2022. The primary focus of this report is the voting results on key corporate governance and financial matters. Investors will be interested to note that all proposed items were overwhelmingly approved by shareholders, indicating strong support for the company's management and strategic direction. Specifically, the election of Class I directors received substantial support, with all nominees elected to serve until the 2025 Annual Meeting. Furthermore, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year 2022, a crucial vote of confidence in the company's financial oversight. Finally, an advisory vote on executive compensation was also approved, suggesting shareholder satisfaction with the remuneration of the company's named executive officers.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jun 2, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing a significant amendment to its Immuno-Oncology License and Collaboration Agreement (IO LCA) with Sanofi Biotechnology, effective upon the A&R Effective Date. This amendment fundamentally restructures the parties' collaboration, granting Regeneron sole worldwide rights to develop and commercialize Libtayo® (cemiplimab). This shift represents a major strategic move for Regeneron, consolidating control over a key asset and streamlining its commercialization efforts. The financial implications of this agreement are substantial. Regeneron will make a $900 million upfront payment to Sanofi, along with potential milestone payments. Post-amendment, Regeneron will retain all Libtayo profits, paying Sanofi an 11% royalty on net product sales through March 2034, and also reimbursing Sanofi for certain development costs through a royalty mechanism. Additionally, an amendment to the Antibody LCA increases Regeneron's share of profits used for development cost reimbursement. Investors should monitor the impact of these payments and the transition of commercial responsibilities on Regeneron's near-term financial performance and its long-term profitability of Libtayo.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 4, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) announced its first quarter 2022 financial and operating results via a press release filed on May 4, 2022. This 8-K filing primarily serves to furnish the aforementioned press release, which contains the detailed results for the quarter ended March 31, 2022. Investors should refer to the press release (Exhibit 99.1) for specific financial figures, including revenue, net income, and earnings per share, as well as operational highlights and management commentary. While the 8-K itself is concise, it signals the release of key performance indicators for Regeneron. Investors will be looking for updates on the performance of their key drugs, progress in their pipeline, and any strategic initiatives discussed in the press release. The furnished press release is the primary source of actionable financial data and operational insights for this period.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Mar 8, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing material definitive agreements related to its corporate headquarters and laboratory space. The company, through its subsidiary Old Saw Mill Holdings LLC, has extended a $720.0 million lease financing agreement for its New York-based facilities. This extension spans five years, moving the maturity date from March 2022 to March 2027. The amended agreements involve a restated participation agreement and a restated lease, which govern the financing and the company's use of the property. These extensions provide continued operational stability and maintain the existing financing structure for these critical assets. The terms include variable interest rates based on SOFR plus a spread and margin, and Regeneron continues to operate under a triple-net lease structure for the facility. The company retains options for further extension or a potential purchase of the facility at maturity.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 4, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 4, 2022, primarily to report its financial and operating results for the fourth quarter and full year ended December 31, 2021. The press release, furnished as Exhibit 99.1, contains the company's performance data. Investors should refer to this press release for detailed financial metrics, including revenue, earnings, and operational updates. While the 8-K itself is a notification of the release, the substance of the investor update lies within the provided press release. This filing serves as the official communication channel for the company's latest performance figures, impacting investor sentiment and future strategic outlook.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 10, 2022)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 10, 2022, to disclose preliminary financial and operational updates provided at the 40th Annual J.P. Morgan Healthcare Conference. The key takeaway for investors is the strong performance of two of its major products. U.S. net product sales for EYLEA® (aflibercept) Injection reached approximately $5.79 billion for the full year 2021, with $1.54 billion in the fourth quarter alone. Furthermore, REGEN-COV® (casirivimab and imdevimab) demonstrated exceptional sales, generating approximately $5.82 billion for the full year 2021, including a significant $2.29 billion in the fourth quarter. These preliminary figures highlight substantial revenue contributions from these key therapies and provide investors with an early look at the company's recent performance ahead of official earnings releases.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 4, 2021)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 3, 2021, to report its third-quarter 2021 financial and operating results. The company announced its Q3 2021 earnings, providing key financial metrics and operational updates. Investors should refer to the press release furnished as Exhibit 99.1 for detailed information regarding these results. The filing itself is primarily procedural, incorporating the press release which contains the substantive financial and operational data. This press release details the company's performance during the quarter ended September 30, 2021, and is the primary source of information for understanding Regeneron's recent financial standing and business developments.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 16, 2021)
Regeneron Pharmaceuticals, Inc. (REGN) announced on September 14, 2021, a significant amendment to its existing supply agreement with the U.S. Government, acting through the Army Contracting Command. This amendment secures an order for an additional 1.4 million doses of REGEN-COV™ (casirivimab and imdevimab), the company's COVID-19 antibody cocktail. This agreement represents a substantial financial commitment, with the U.S. Government obligated to purchase these doses for a total of $2.940 billion, priced at $2,100 per dose. The U.S. Government will acquire the doses at the lowest therapeutic dose (excluding pediatric) authorized or approved by the FDA by the delivery date. Regeneron is committed to delivering these doses by January 31, 2022, with specific minimum delivery targets for each month leading up to that date. The agreement also includes standard U.S. Government contract terms, such as the right to terminate for convenience, with provisions for Regeneron to receive compensation for work performed in such an event. This expanded contract underscores the continued demand for REGEN-COV™ and provides a significant revenue stream for Regeneron.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 5, 2021)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 5, 2021, to report its financial and operating results for the second quarter ended June 30, 2021. The filing primarily incorporates a press release detailing these results. Investors should note that this information, while provided, is furnished and not considered "filed" for certain SEC purposes, meaning it's not subject to the liabilities of Section 18 of the Exchange Act or automatically incorporated into other filings unless explicitly stated. The key takeaway for investors is the release of the company's latest quarterly performance data. While the 8-K itself is a procedural filing, the attached press release (Exhibit 99.1) contains the substantive financial and operational metrics that are crucial for evaluating REGN's business performance, revenue drivers, and profitability for the period. Investors will need to refer to the press release for specific details on sales, earnings, and any significant business updates provided by the company.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 16, 2021)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 16, 2021, detailing the results of its Annual Meeting of Shareholders held on June 11, 2021. The primary focus of the filing is the voting outcomes on key corporate governance matters. All director nominees were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2021 was ratified by a substantial majority of shareholders. These votes indicate continued shareholder confidence in the current board of directors and the company's financial oversight. Investors can take comfort in the overwhelming support for the auditor ratification, suggesting strong governance practices. The director elections, while showing varying degrees of support among nominees, ultimately resulted in the continuation of the nominated Class III directors.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 6, 2021)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 6, 2021, to furnish a press release detailing its financial and operating results for the first quarter ended March 31, 2021. This filing primarily serves to make the Q1 2021 earnings announcement publicly available through the SEC, including key financial metrics and operational updates that are crucial for investors to assess the company's performance and outlook. The press release, incorporated by reference, likely contains information on revenue, earnings per share, product sales, and potentially updates on pipeline development and strategic initiatives. Investors should refer to the furnished press release (Exhibit 99.1) for the specific details of Regeneron's Q1 2021 performance, as this 8-K filing itself does not provide the numerical data but rather points to the official announcement.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 5, 2021)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on February 5, 2021, primarily announcing its financial and operating results for the fourth quarter and full year ended December 31, 2020. The key takeaway for investors is the release of these results via a press release (Exhibit 99.1), which provides the most recent performance data for the company. Investors should review this press release for detailed figures on revenue, profitability, and other operational metrics. While the 8-K itself does not contain the financial details, it serves as the official notification that these results are now publicly available. The filing explicitly states that the information furnished in the press release is not considered 'filed' for certain regulatory purposes, meaning its inclusion here is for disclosure purposes and not subject to the same liabilities as a formally filed registration statement. Investors are directed to the attached press release for a comprehensive understanding of Regeneron's 2020 performance and its implications for future outlook.